GlassScriptPhysician profile
Laura M Seipt
NPI 1144818600
$7,749.38
in general payments reported to CMS, 2019-2025
55 companies · $2,556 in 2025
The $2,556 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $919 · 2023: $2,022 · 2024: $1,954 · 2025: $2,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,098 · Education: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,098.33 |
| Education | $433.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $631.17 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $589.86 | 2023-2025 | |
| Celgene Corporation | $583.55 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Glaxosmithkline, LLC. | $380.43 | 2021-2025 | Ojjaara, Shingrix |
| Daiichi Sankyo INC. | $358.38 | 2022-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $354.51 | 2022-2025 | Rybrevant, Darzalex, Erleada |
| E.R. Squibb & Sons, L.L.C. | $347.63 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Seagen INC. | $339.24 | 2022-2025 | Adcetris, Tukysa |
| Incyte Corporation | $314.60 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Jazz Pharmaceuticals INC. | $277.24 | 2021-2025 | |
| Pfizer INC. | $245.37 | 2023-2025 | |
| Abbvie INC. | $231.96 | 2024-2025 | |
| Novocure INC. | $226.97 | 2021-2024 | Optune, Optune Lua (Novottf-200t) |
| Genentech USA, INC. | $196.31 | 2023-2025 | Phesgo, Tecentriq, Alecensa |
| Ipsen Biopharmaceuticals, INC | $156.36 | 2023-2025 | Onivyde, Somatuline Depot |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $149.19 | 2023-2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $137.11 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $127.89 | 2022-2025 | Libtayo |
| Acrotech Biopharma INC. | $118.47 | 2022-2025 | Beleodaq |
| Idorsia Pharmaceuticals US INC | $117.45 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $111.15 | 2024-2025 | |
| Lilly USA, LLC | $102.85 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.23 | 2023-2025 | Gilotrif |
| Astrazeneca Pharmaceuticals LP | $98.85 | 2022-2025 | Imfinzi, Calquence |
| Genzyme Corporation | $94.90 | 2022-2025 | |
| Geron Corporation | $93.42 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $82.25 | 2023-2025 | Qinlock, Romvimza |
| Karyopharm Therapeutics INC. | $78.97 | 2023-2025 | Xpovio |
| Alnylam Pharmaceuticals INC. | $71.08 | 2022-2023 | Givlaari |
| Adaptive Biotechnologies Corporation | $67.24 | 2022-2024 | Clonoseq |
| Beigene USA, INC. | $67.14 | 2023-2025 | Brukinsa |
| Gilead Sciences, INC. | $66.61 | 2022-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $63.95 | 2023 | Krazati |
| Beone Medicines USA, INC. | $57.59 | 2025 | Brukinsa |
| G1 Therapeutics, INC. | $57.02 | 2022-2023 | Cosela |
| Amgen INC. | $55.01 | 2022 | |
| Eisai INC. | $51.89 | 2024 | |
| Pharmacosmos Therapeutics INC. | $46.09 | 2023-2024 | Monoferric |
| Recordati_rare_diseases_inc. | $43.35 | 2023 | Panhematin |
| Servier Pharmaceuticals LLC | $42.52 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $38.43 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Kyowa Kirin, INC. | $38.09 | 2025 | |
| Taiho Oncology, INC. | $37.98 | 2024-2025 | |
| Tersera Therapeutics LLC | $37.88 | 2023 | Xermelo |
| Takeda Pharmaceuticals U.S.A., INC. | $36.26 | 2023-2024 | Ninlaro |
| Sobi, INC | $35.92 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $33.86 | 2022-2023 | Ultomiris |
| Immunocore Limited | $24.39 | 2024 | Kimmtrak |
| Iovance Biotherapeutics, INC. | $23.10 | 2025 | Amtagvi |
| Array Biopharma INC | $20.95 | 2024 | Lorbrena, Mektovi, Braftovi |
| Azurity Pharmaceuticals, INC. | $20.61 | 2025 | Danziten |
| Stemline Therapeutics INC. | $20.31 | 2025 | Orserdu |
| Caris Mpi, INC. | $16.64 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $15.82 | 2024 | Padcev |
| Coherus Oncology, INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Seipt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.